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PHYSICAL ACTIVITY–INDUCED 
NEUROPROTECTION IN PARKINSON’S 
DISEASE IS MEDIATED BY 
NEUROTROPHIC FACTORS 




DEPARTMENT OF THE BIOMEDICAL SCIENCES 




Parkinson’s disease (PD) is a progressive neurological movement disorder manifested by motor 
and non-motor disturbances that are brought about by degeneration of dopaminergic (DAergic) 
neurons in the substantia nigra (SN), causing a decline in dopamine (DA) levels in the striatum. 
Pharmacological and surgical treatment of PD are often ineffective, cause severe side effects, and 
the benefits seen decrease with disease progression; therefore, there is a need to seek new therapies. 
Physical activity (PA), which includes exercise, is able to improve many systems in the body, 
including motor and cognitive function, and may serve as a viable option for remedy of PD. Due 
to many limitations, human studies are unlikely to explain whether such intervention may be 
neuroprotective in PD patients; therefore, the use of animal models is imperative. PA in animal 
models of PD has neuroprotective effects on DAergic neurons and current hypotheses infer a 
central role of neurotrophic factors (NTFs); however, the exact mechanisms of their action have 
yet to be elucidated. In the present review, studies will be discussed that highlight how PA 
increases NTF mobilization leading to protection of DAergic neurons and improved motor 
performance. Furthermore, this review will explore NTF influence in several postulated aberrant 
cellular processes where intervention could be made to treat PD, including neuroplasticity and 
synaptic transmission, angiogenesis and vasodilation, mitochondrial dysfunction through 
oxidative stress and protein aggregation, and neuroinflammation. 
 
INTRODUCTION 
PD was first described in 1817 by James Parkinson, described as a “Shaking Palsy”, and 
eventually went on to bear his name [1]. PD is the commonest neurodegenerative disease after 
Alzheimer’s disease, affecting roughly 1% of adults over the age of 60 [2] and is currently the 14th 
leading cause of death in the United States [3]. PD is a progressive neurological disorder that is 
characterized by depigmentation of the SN caused by the selective loss of DAergic neurons and 
the presence of misfolded protein aggregates known as Lewy Bodies (LBs) [4]. 
Because it is a progressive disease, symptoms generally develop gradually and can be 
classified as motor and non-motor. Motor symptoms are usually used to diagnose PD and 
commonly include tremor, bradykinesia (slowness of movement), stiffness, and postural instability 
[3]. Non-motor symptoms may coincide with PD or may appear before the diagnosis is made (pre-
motor symptoms) [5]. Non-motor symptoms include, but are not limited to, lack of emotional 
involvement and interest (apathy), inability to experience pleasure from activities that were 
otherwise found enjoyable (anhedonia), memory problems, loss of smell and taste, excessive 
sweating, constipation or urinary problems, depression or mood disturbances, skin problems, 
daytime drowsiness, and disruptions in sleep [5,6,7]. 
The cause of PD, while still unknown, is likely multifactorial. It was originally thought that 
environmental factors were the predominant cause of PD, especially after the influenza outbreak 
of 1918, when a group of affected individuals developed postencephalitic Parkinsonism [8]. The 
environmental hypothesis was supported further when four individuals developed Parkinsonism 




phenyl-1,2,5,6-tetrahydropyridine (MPTP) with smaller amounts of 1-methyl-4-phenyl-4-
propionoxy-piperidine (MPPP) ‒ in the early 1980s [9]. Since this time, a number of environmental 
factors have been implicated as a cause of PD, including metals, pesticides, farming or rural life, 
industrial toxins, high caloric intake, and head trauma [10,11]. Although a large part of the 1900s 
focused on the environmental factors that lead to PD, the current knowledge on the underlying 
causes of PD has changed greatly. A large percentage of patients (>85%) with late-onset or 
idiopathic PD do not seem to have inherited the disease, but a family history of PD puts an 
individual at high risk, as some studies have shown large families with evident Mendelian-pattern 
inherited PD (<10%) [12]. While the etiology remains elusive, several mechanisms, including 
oxidative stress, mitochondrial dysfunction, disrupted proteolysis, neuroinflammation, and 
excitotoxicity are involved in the pathophysiology of the disease leading to neuronal cell death 
[13,14,15]. 
Pharmacological and surgical treatments are current therapies for PD which can help many 
patients, but benefits are limited. Pharmacological treatments, the current gold standard, are largely 
based on DA replacement such as DA precursors (levodopa, L-DOPA), DA agonists (amantadine, 
apomorphine), MAOB inhibitors (selegiline, rasagiline) [16]. Other potential drug treatments 
include COMT inhibitors (entacapone, tolcapone), and A2A antagonists (caffeine, tozadenant) 
[17]. When medication cannot treat the severity of PD symptoms, deep brain stimulation is a 
surgery that sends electrical signals to the SN. Stimulation of the SN and surrounding areas (e.g., 
globus pallidus, subthalamic nucleus, caudal zona incerta) has shown to treat motor symptoms 
dyskinesia and tremor through a mechanism of neurogenesis and neuroplasticity, which is likely 
to improve long-term symptoms [16,18]. Although, short-term, various medical and surgical 
therapies alleviate symptoms of PD, there is a large list of adverse effects (Table 1) [19] and, to 




The presymptomatic phase of PD is estimated to be 10-20+ years [21], which allows for 
the potential to test non-pharmacological interventions. PA may serve as a non-invasive, non-
pharmacological treatment of PD that has no side effects yet has proven benefits for multiple organ 
systems including the central nervous system (CNS) [22,23,24]. Recent studies display that regular 
PA, such as aerobic exercise, strength training, and flexibility can enhance brain plasticity ‒ 
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playing a vital role in the improvement of motor and cognitive function [25]. Although a vast 
amount of evidence supports that PA could be used as a neuroprotective agent to combat PD, the 
mechanism underlying the diminished risk is still not fully understood [26] and is difficult to study 
in a human model. 
Studies in rodents that have been subjected to PA around the time of application of neural 
insult, to simulate PD, have shown much promise to elucidate the etiology of PA-induced 
neuroprotection. Neurotoxic agents that are most often used for this purpose include MPTP and its 
active metabolite 1-methyl-4-phenylpyridine (MPP+), 6-hydroxydopamine (6-OHDA), and 
lipopolysaccharide (LPS). Many of these studies have found that exercise, a subcategory of PA, 
reduced the loss of DAergic neurons in the SN through a neuroprotective mechanism involving 
upregulation of NTFs. 
NTFs are peptides required for the maintenance, survival, specification, and maturation of 
specific neuronal populations [27]. Through a widely renowned process known as the 
“neurotrophic factor hypothesis”, neurons compete for a limited supply of these peptides during 
development, which are produced by target tissues; neurons that fail to receive an adequate supply 
perish by means of programmed cell death, known as apoptosis [28]. In the post-developmental, 
mature organism, NTFs are essential for maintaining neuronal functionality and their specific 
phenotype [29]. NTFs have also been shown to have the means of modifying neuronal dysfunction, 
inflammatory reactions, and neural plasticity during periods of pathological states such as 
neurodegeneration or aging [29]. 
More than 20 different NTFs have been identified and fall into one of four families of 
related molecules: (i) the neurotrophin family; (ii) the glial cell line-derived neurotrophic factor 
(GDNF) family of ligands (GFLs); (iii) the neurotrophic cytokines, or “neurokines”; and (iv) the 
newer, unconventional, cerebral dopamine neurotrophic factor (CDNF) and mesencephalic 
astrocyte-derived neurotrophic factor (MANF) [27,30]. This review will focus primarily on NTFs 
that have been extensively studied in animal models and are known to act through pathways that 
are disrupted in PD. The commonest being BDNF, GDNF, VEGF, and IGF-1. 
Up to this point, an overwhelming amount of evidence supports PA as an effective 
prevention or therapy for PD; however, the mechanisms underlying these claims are not fully 
understood [26]. While this review will give a short background and discussion of several signaling 
cascades and cellular mechanisms, it is not meant to take the place of a more detailed review on 
each specific topic covered. This goal of this article is to analyze papers based on studies using 
animal models of PD in order to investigate the effect of PA on several mechanisms that have been 
proposed to explain the effects of PA on neuroprotection in PD, centered around NTF action. These 
include increased NTF synthesis and release, protection of DAergic neurons and improved motor 
function, enhanced neuroplasticity and synaptic transmission, increased angiogenesis and 
vasodilation, improved mitochondrial function through resistance to oxidative stress and reduced 










PA Type PA Start 
Timing, 
Duration 











Treadmill 6 wks after 
6-OHDA 
16 m/min, increased 
by 2 m/min every 3 





al., 2010 [32] 
Mouse / 
MPTP 
Treadmill 4 wks after 
MPTP 
18 m/min for 40 
min/d; 5 d/wk + + 
NA 










+ + + 




Treadmill 1 mo before 
6-OHDA 
3 d/wk NA 
+ 
NA 

















3 mo before 
MPTP 
4.8 km/d NA 
+ 
NA 






4 wks after 
6-OHDA 
2% body weight 





al., 2017 [38] 
Rat / 6-
OHDA 
Treadmill 4 wks before 
6-OHDA 
15 m/min for 30 
min/d; 5 d/wk + + + 




Treadmill 8 wks after 
MPTP 
10 m/min for 60 
min/d; 5 d/wk 
NA 
+ + 




Treadmill 8 wks after 
MPTP 
10 m/min for 40 
min/d; 5 d/wk + + + 




Treadmill 8 wks after 
MPTP 
10 m/min for 60 
min/d; 5 d/wk 
NA 
+ + 









Up to 15 m/min for 




al., 2019 [43] 
Rat / 6-
OHDA 
Treadmill 4 wks after 
6-OHDA 
15 m/min for 30 min 
(mild) or up to 120 
min (progressive); 5 
d/wk 
+ + + 




Treadmill 4 wks after 
6-OHDA 
10 m/min for 40 
min/d; 3 d/wk + + + 




Treadmill 4 wks before 
6-OHDA 
3 d/wk NA 
+ + 




Treadmill 4 wks after 
6-OHDA 
11 m/min for 30 
min/d; 5 d/wk 
NA 
+ + 




Treadmill 2 wks after 
MPTP 



















Treadmill 4 wks after 
MPTP 
12 m/min for 30 
min/d; 5 d/wk 
NA 
+ + 




Treadmill 4 wks after 
6-OHDA 
11 m/min for 30 min; 
5 d/wk + + + 







































Treadmill 8 wks before 
6-OHDA 
13-17 m/min for 25 
min/d; 3 or 4 d/wk + + + 




Treadmill 6 wks after 
MPTP 
10-24 m/min; 5 d/wk NA 
+ 
NA 
Tsou et al., 
2015 [56] 
Rat / MPP+ Treadmill 4 wks before 
MPP+ 
12-15 m/min for 60 




Wu et al., 2011 
[57] 
Mouse / LPS Treadmill 4 wks before 
LPS 
10 m/min for 60 
min/d; 5 d/wk + + + 
HPT 6 
 




Treadmill 2 wks after 
6-OHDA 
2 m/min for 5 min, 3 






PHYSICAL ACTIVITY INCREASES NEUROTROPHIC 
FACTOR SYNTHESIS AND RELEASE 
Table 2 gives a simplified overview of numerous studies that show positive effects of PA 
on motor performance, NTF mobilization, and protection of DA neurons in neurotoxin-induced 
rodent PD models. The exact mechanism by which PA increases the mobilization of NTFs is 
complex and not yet fully understood. However, it has been shown that PA is accompanied with 
increased metabolism, due to a larger energy requirement. Peroxisome proliferator-activated 
receptor ℽ coactivator 1ɑ (PGC-1ɑ) is one of many transcriptional regulators that acts as a 
metabolic sensor and alters gene expression in response to metabolic changes [59]. With PA in 
mice, Steiner et al [60]. found that PGC-1ɑ is overexpressed in the brain and, through activation 
by silent information regulator 1 (SIRT1), induces synthesis of mitochondria (i.e., mitochondrial 
biogenesis). 
Following mitochondrial biogenesis, PGC-1ɑ has also been shown to increase oxidative 
phosphorylation, and thus, energy production [61]. Metabolic increases, such as those seen with 
PA, confer a greater amount of circulating energy metabolites and intermediates; especially ketone 
bodies like D-β-hydroxybutyrate (DBHB) and acetoacetate, derived from acetyl-CoA. Several of 
these metabolites have shown an ability to circulate throughout the body and serve as an energy 
source for several tissues, 
including the brain by crossing 
the blood brain barrier (BBB). 
These endogenous energy 
metabolites are capable of 
inducing promoters for the 
genes of NTFs, augmenting 
their synthesis and release (Fig 
1). For example, in mice subject 
to voluntary running for 4 
weeks, researchers found 
increased levels of DBHB, 
which led to amplified BDNF 
expression [62].  
Table 2. A simplified overview of studies which subjected rodent animal models to some form of PA 
with a PD lesion displaying the compound used for neurotoxic insult, form of PA, PA start timing with 
respect to the PD lesion, duration of PA, and analysis of NTF, DA/TH, and motor function. “+” = an 
improvement or increase, NA = not examined in the study. 
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Although PGC-1ɑ mainly resides within mitochondria to regulate several if its functions, 
Safdar et al [63]. found that PGC-1ɑ translocates from between mitochondria and the nucleus to 
facilitate its action. While it has been known that PGC-1ɑ binds to promoters of nuclear-encoded 
mitochondrial genes [64], it is entirely plausible that PGC-1ɑ, itself, acts as a signal of increased 
energy production, giving rise to increased NTF production to promote transcellular signaling for 
survival of larger populations of neurons in the CNS. It is apparent that there are multiple 
mechanisms taking part in the PA-induced NTF expression, yet enhanced metabolism leading to 
increased energy production and levels of metabolic intermediates displays one possible 
explanation for increased NTF expression and mobilization. 
 
PHYSICAL ACTIVITY PROTECTS DOPAMINERGIC NEURONS 
Many of the studies suggest that exercise can promote neuroprotection, through the 
upregulation of NTFs, against neurotoxin treatment. Survival of DAergic neurons is mediated by 
transcriptional regulation of the tyrosine hydroxylase (TH) gene that is involved in DA 
metabolism. TH is an enzyme that converts tyrosine to L-dihydroxyphenylalanine (L-DOPA), 
which is then converted to DA by the L-amino acid decarboxylase (AADC) aromatic enzyme. In 
addition to DA, several of its metabolites, including 3,4-dihydroxyphenylacetic acid (DOPAC) 
and homovanillic acid (HVA) can be used to report DA concentrations as a measure of DAergic 
function and survival. TH levels can also be used as a marker of DAergic neurons, due to the 
finding that increased TH activity promotes their survival [65]. In the proceeding text in this 
section, several studies will be summarized to exemplify exercise-induced protection of DAergic 
neurons and improved motor performance of PD-lesioned exercised (PDE) compared to PD-
lesioned sedentary (PDS) animals. 
Protection of DAergic neurons was displayed in two studies by Gerecke et al. with 
voluntary running wheel exercise prior to MPTP treatment in mouse PD models. The first study 
[35] investigated the critical duration of exercise necessary for neuroprotection of DAergic 
neurons and found that 1 month provided no neuroprotection, 2 months showed partial protection, 
and 3 months of exercise completely protected DAergic neurons in the SN from subsequent 
neurotoxin treatment. The second study [36] used this data and subjected mice to 90 days (3 
months) of voluntary exercise with or without a knockout in the BDNF gene, to test NTF-induced 
neuroprotection from exercise. Results showed that 90 days of unrestricted running in wild-type 
mice completely protected against MPTP-induced neurotoxicity, while mice with a knocked out 
BDNF gene were not protected from MPTP-induced DAergic neuron loss in the SN. Lastly, Wu 
et al [57]. showed that LPS-treated mice had a reduction in the number of DAergic neurons and 
BDNF levels in the SN. They then showed that 4 weeks of treadmill exercise prior to LPS injection 
prevented the loss of DAergic neurons, and elevated DA and DOPAC in the SN and striatum. The 
critical role that BDNF played in the exercise-induced neuroprotection was highlighted by their 
findings that blocking the BDNF receptor, and thus its action, abolished protection against 
DAergic neuron loss. 
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Several studies also display effects of exercise during neurotoxic insult. Lau et al. [42] used 
a program that consisted of treadmill exercise 1 week prior, 5 weeks during, and 12 weeks after 
MPTP hydrochloride + probenecid treatment in a mouse PD model. Results showed a significant 
increase in the number of DAergic neurons in the SN when compared to PDS mice (Fig 2). 
Additionally, increases in levels of TH, DA, and dopamine active transporter (DAT) were seen in 
PDE mice. With a NTF analysis, researchers discovered elevated levels of BDNF and GDNF in 
the striatum and SN of PDE mice; importantly, NTF levels in the PDE group were higher than 
both the PDS and non-PD controls. Similarly, Tuon et al. [54] investigated the effects of 
incremental treadmill exercise 8 weeks after 6-OHDA treatment and found striatal increases of 




A larger number of studies compiled have monitored the neuroregenerative effects of 
exercise when the training began after neurotoxic insult. Koo et al [40]. subjected mice to 8 weeks 
of treadmill exercise after an MPTP lesion and showed inhibition of DAergic neuron loss in the 
SN by promotion of TH and DAT. Real et al [44]. exercised rats for 4 weeks after injection of 6-
OHDA and found rescue of TH and BDNF levels in the SN of PDE compared to PDS groups. 
They, too, validated the action of BDNF involvement in neuroprotection by showing that a BDNF 
receptor blockade reversed the neuroprotective effects of exercise. Cohen et al [33]. tested forced 
limb use by placing a cast on the rat forelimb for 7 days following 6-OHDA administration to the 
medial forebrain bundle (MFB). The cast was placed on the forelimb ipsilateral to the injected 
MFB, forcing the animal to use the contralateral limb, in which motor function was negatively 
affected by the 6-OHDA injection. Casted animals (PDE) were found to have higher levels of 
GDNF in the striatum corresponding to the overworked limb compared to non-casted animals 




Tajiri et al [50]. examined the effects of treadmill exercise for 4 weeks following a 6-
OHDA lesion on DA neurons and NTFs. Results showed a preservation of DAergic-fibers in the 
striatum and DAergic-neurons in the SN for PDE compared to the PDS group. Furthermore, they 
found that both BDNF and GDNF increased in control- and 6-OHDA-treated sides of the striatum 
in the PDE group. Lastly, Mohammadi et al [43]. tested mild vs progressive treadmill exercise for 
4 weeks in rats following a 6-OHDA lesion. They found that with progressive treadmill exercise, 
but not mild, there were increases in both DA and TH in the striatum. Additionally, to a larger 
degree in progressive exercise, there were increases in striatal NTFs: MANF, CDNF, and NGF. 
 
PHYSICAL ACTIVITY IMPROVES MOTOR PERFORMANCE 
In order to assess motor function, several tests were carried out across various studies. The 
most used was the rotational behavior test (Fig 3a,b), which has become a mainstay for testing the 
extent of motor impairment from loss of nigrostriatal or mesolimbic DAergic neurons due to 
neurotoxic insult. The extent that various authors are concerned with this test is its ability to 
demonstrate rescue of DAergic neurons from cell death. 
In this test, rodents are placed in a rotameter, a bowl-like apparatus with a flat center and 
steep walls, and injected with amphetamine or apomorphine to increase motor activity. In control 
rodents (those not lesioned), the animal exhibits exploratory behavior, but not high numbers of 
rotational movements. Lesioned animals, however, display profound asymmetrical rotations, i.e., 
often turning in one direction over the other, in the forelimb contralateral to the lesion. This model 
is useful in that it allows for assessment of DA neuron loss and functional changes that results 





In the studies used throughout this review as evidence of exercised-induced 
neuroprotection, 10 of them [31,33,38,43,44,45,46,52,54,58] performed the rotation test and all 10 
of them showed a positive result of exercise therapy, where neurotoxin-induced PD rodents 
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displayed a significant decrease in the number of asymmetrical rotations (Fig 3c). In the studies 
that showed this positive result of exercise, only 5 of them [33,38,43,44,54] concurrently 
monitored and studied the effects of NTF action; therefore, it becomes imperative to examine NTF 
action at the cellular level in order to elucidate the beneficial effects of NTF action in animal 
models of PD. 
 
MOLECULAR MECHANISMS OF NEUROTROPHIC FACTOR ACTION 
In the early 1990’s it was known that PA played roles in improving neuronal survival in 
response to brain insult by promoting neuronal vascularization and stimulating neurogenesis. Since 
that time, it has been discovered that many of these beneficial aspects are due to direct action on 
molecular machinery in the CNS itself, rather than through improvements in general health [69]. 
The preceding sections summarized how PA attenuated the reduction of DAergic neurons and 
mobilized NTFs to provide motor improvements in animal neurotoxin-induced models of PD. Now 
this reivew will discuss the possible underlying molecular mechanisms of these findings. Although 
these mechanisms are not all well-established, large amounts of evidence suggest that NTFs are 
the key mediators of the beneficial effect of PA [70] and, due to an overwhelming amount of 
literature on the cellular effects of various NTFs, a large portion of this section will be dedicated 
to those that have been highly implicated in PD. 
 
BDNF 
BDNF has roles in neuronal and glial development, neuroprotection, and synaptic 
interactions which are critical for cognition and memory [71]. It is likely the most highly studied 
NTF for its role in PD, and has been shown to promote the survival, function, and differentiation 
of SN DAergic neurons [72]. ProBDNF, the BDNF precursor, undergoes proteolytic cleavage to 
form mature BDNF, which acts through a high affinity tyrosine receptor kinase B receptor (TrkB) 
on cell surfaces, leading to the activation of downstream MAPK, PI3K/Akt, and PLCℽ pathways 
[73,74]. In a study that investigated the effects of PA on depressive symptoms in PD, Tuon et al 
[75]. found a significant decrease in striatal levels of proBDNF, BDNF, and TrkB upon treatment 
with 6-OHDA; however, with PA, there was a reversal of the diminished expression and 
prevention in depressive-like behavior. Thus, researchers proposed that the beneficial effects of 
PA were likely a result of increased maturation of proBDNF to BDNF. 
Using in situ hybridization, high expression levels of BDNF are apparent in many midbrain 
structures and the cerebellum, with a lower expression level in the striatum [76]. BDNF expression 
is particularly high in the SN, but is severely attenuated in PD. Parain et al [77] presented this by 
detecting that 65% of all melanin-containing neurons in the SN were immunoreactive for BDNF 
while, in PD patients, only 9.6% of these pigmented neurons were reactive for BDNF. 
Additionally, previous studies suggest that exogenous BDNF administration can increase the 
survival and/or aid in the recovery of injured DAergic neurons when treated with MPP+, with or 
without BDNF as a potential therapeutic agent [78]. 
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In cultured hippocampal neurons it was shown that there is a rapid increase of TrkB 
expression after BDNF treatment followed by a reduction after several days through a process of 
transcriptional regulation [79]. Neuronal activity, which PA is known to boost, generates a 
sustained mode of activation for TrkB and its downstream signals, leading to attenuation of 
neuronal cell death and amplified dendritic branching [74]. In both non-pathological and 
pathological conditions, both proBDNF and BDNF are secreted, but have opposite effects. 
ProBDNF preferentially binds the pan-neurotrophin receptor (p75NTR) [80] while mature BDNF 




GDNF has been shown to play a significant role in the development and survival of 
midbrain DAergic neurons as well as spinal motor neurons via its neuroprotective role of reducing 
neuronal atrophy that coincides with age-related deficits [83]. It is crucial for the maintenance of 
neuronal morphological and neurochemical phenotypes and protects DAergic neurons from toxic 
damage [84]. It has been shown that GDNF is approximately 5-10 times more potent than BDNF 
in promoting DAergic neuron survival [85]. GDNF acts through the receptor tyrosine kinase 
rearranged during transcription (Ret), but the activation of Ret requires association with the 
membrane-bound protein GDNF family receptor ɑ (GFRɑ) [86]. Formation of the Ret-GFRɑ 
complex induces activation of downstream signaling including, MAPK, PI3K/Akt, and PLCℽ 
pathways [87]. 
In a study by Boger et al., a heterozygous partial deletion of the Gfrɑ1 gene in aging mice 
(26 months) showed a decrease in DAergic fiber density in the striatum accompanied by a lower 
number of DAergic neurons in the SN, and an increased sensitivity of nigrostriatal DAergic 
neurons to MPTP toxicity [88], suggesting a pivotal role of GFRɑ in trophic neuroprotection by 
GDNF signaling. As a NTF, GDNF promotes the DA phenotype of DAergic neurons and may, in 
this way, exert some of its neuroprotective actions. Through its action, GDNF increases 
transcription factors (Nurr1, Pitx3) that participate in the expression of genes involved in DA 
metabolism including TH, DAT, AADC, and vesicular monoamine transporter (VMAT) [89]. 
 
VEGF 
VEGF was originally believed to be a factor that played regulatory roles in vascular growth 
and development [90]; in more recent times, it has also been shown to have direct action on 
neuronal populations such as, stimulating axonal growth and guidance [91], stimulating 
neurogenesis [92], regulating neuronal migration [93], and promoting dendrite patterning and 
synaptic plasticity [94]. The VEGFs are a family of growth factors that include VEGF-A, VEGF-
B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor [95]. The biological activity of the 
VEGFs is mediated through the binding to two classes of receptor. The first being VEGF tyrosine 
kinase receptors 1-3 (VEGFR1-3), and the second, non-tyrosine kinase receptors, being neuropilin 
(NP-1, NP-2) which function as co-receptors for the VEGFRs [96]. Upon ligand binding, VEGFR 
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undergoes autophosphorylation, activating intracellular signaling pathways including PI3K/Akt 
and MAPK cascades, which have been shown to protect motor neurons in cell culture [97]. 
Two studies by Falk et al. showed how VEGF-B serves as an inducible neuroprotectant in 
a model of neurodegeneration. In the first [98], researchers used rotenone, a neurotoxin and 
commonly used pesticide that produced a well-characterized PD model, on rat midbrain neuronal 
cultures. In this study results demonstrated an upregulation of several genes post-rotenone 
treatment: notably, an increased transcriptional activation of VEGF-B and unchanged levels of 
VEGF-A. The same in vitro study using rat midbrain cultures, rotenone was used either alone, or 
with the addition of VEGF-B one hour prior to rotenone treatment. Results showed a significant 
loss of DAergic neurons compared to untreated control cells while, in cultures treated with VEGF-
B, there was a neuroprotective rescue of cell loss. In the second [99], VEGF-B’s neuroprotective 
effects were tested in vivo using a unilateral 6-OHDA rat PD model, with an intrastriatal injection 
of VEGF-B prior to the neurotoxic treatment. In VEGF-B-treated animals there was an 
improvement in PD behavior, partial protection of DAergic fibers in the striatum, and a partial 
rescue of DAergic neurons in the SN, indicating a neuroprotective effect. 
Additionally, in two studies by Yasuhara et al., VEGF was found to be neuroprotective 
against cell death in mesencephalic neurons in vitro [100]. Further, in vivo using rat 6-OHDA 
models, VEGF was continuously infused into the striatum where it preserved DAergic neurons 
from insult and reduced the number of rotations in the amphetamine-induced rotational behavior 
test [101]. Results indicated that VEGF promotes neuroprotection indirectly by activating the 
proliferation of glia and promoting neurogenesis. 
 
IGF-1 
The insulin superfamily of peptides consists of insulin and insulin-like growth factors 1 
and 2 (IGF-1, IGF-2) [102]. Here, we focus on IGF-1 because it is produced by all cells types in 
the mature brain and is diffusely expressed in many neuronal structures including the cerebellum, 
brainstem, and spinal cord [103]; while IGF-2 is produced at high levels during development, and 
is mostly restricted to the choroid plexus and meninges [104]. IGF-1 signals through the insulin-
like growth factor 1 receptor (IGF-1R) and is regulated by IGF-binding proteins (IGFBPs). 
IGF-1R is a receptor tyrosine kinase that, upon activation and autophosphorylation, signals 
through the PI3K/Akt and MAPK signaling cascades [105,106]. IGF-1 has been proven to exert 
neuroprotective and proliferative function via promotion of cell survival, prevention of apoptosis, 
and stimulation of neurogenesis [107]. It is believed that IGF-1 has a role in PD, rather than general 
survival of neurons in the brain, due to the following: (i) the SN is one of the regions in the brain 
that possesses a substantial density of IGF-1Rs [108], (ii) IGF-1 increases survival of neurons in 
the brainstem including the SN [109], and (iii) IGF-1 rescues DAergic neurons from programmed 
cell death [110]. 
It has been reported that IGF-1 has a positive effect on DAergic neurons in both in vitro 
and in vivo models. Using rat cerebellar neurons, Offen et al [111]. treated cell cultures with high 
concentrations of DA to induce oxidative stress and cause neurodegeneration with or without 
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administration of IGF-1. Addition of IGF-1 to DA-treated cells significantly increased cell survival 
and expression of antiapoptotic proteins [106]. Another in vitro study using neuronal cultures 
reported an IGF-1-mediated rescue of aggregated ɑ-syn toxicity via the activation of PI3K/Akt 
[112]. Lastly, in an in vivo model, activation of the IGF-1R protected against DAergic neuron loss 
in the SN, and alleviated motor deficits in balance and coordination that were induced by 6-OHDA 
in rats [113]. 
 
MANF and CDNF 
In addition to the other well-known NTFs, more recent investigation has displayed that 
MANF and CDNF possess neurotrophic effects on nigral DAergic neurons and neuroprotective 
effects in animal PD models. Importantly, high levels of MANF and CDNF are detected in many 
brain regions including the striatum and SN [114] and protect against DAergic cell death in 6-
OHDA and MPTP models [114]. In vivo, prior to a 6-OHDA lesion, CDNF was administered, and 
induced protection of DAergic neurons in the SN. CDNF was as efficient as GDNF in producing 
long-lasting beneficial motor effects and reduced amphetamine-induced asymmetrical turning 
behavior [115,116]. 
MANF and CDNF appear to be important for ER homeostasis as they are largely confined 
to the endoplasmic reticulum (ER), by a KDEL sequence [115,117]. The belief that these NTFs 
are of high importance to the ER was further backed up with the finding MANF can bind to KDEL 
receptors and ER molecular chaperones [117], which will be discussed in further detail later. These 
NTFs can also be secreted to exert their neuroprotective effects in times of excessive ER stress 
[118]. Many modes of action of these NTFs have been postulated. One possible mechanism is the 
activation of intracellular signaling pathways PI3K/Akt and PLCℽ [114]. 
 
Others NTFs 
There are several other NTFs that have been identified which possess similar functions to 
those previously mentioned. NGF was the first NTF to be discovered and is the canonical member 
of the NGF-superfamily, composed of previously discussed BDNF and neurotrophins (NT)-3, -
4/5, and -6 [119]. Aside from BDNF, the NGF-superfamily is less implicated than other NTFs in 
PD, as it mainly functions on sympathetic and sensory neurons in the peripheral nervous system 
(PNS) and in the development and maintenance of cholinergic neurons in the basal forebrain [120]. 
However, NGF and NT-3, through binding to their receptors, TrkA and TrkC, respectively, are 
known to activate several intracellular pathways including MAPK, PI3K/Akt, and PLCℽ [121] to 
promote differentiation and survival of neurons. Like BDNF, the remaining NGF-superfamily 
members are also synthesized as proNTFs, which show preferential binding for p75NTR [122]. 
CNTF, belonging to the neurotrophic cytokine family, which also includes leukemia 
inhibitory factor (LIF), cardiotrophin-1 (CT-1), and interleukin 6 and 10 (IL-6,10), supports the 
survival of motor and DAergic neurons [123,124]. CNTF signals through a tripartite complex of 
CNTFRɑ, LIFRβ, and GP130, activating several downstream signaling cascades such as MAPK 
and PI3K/Akt. Activation of these pathways result in increased transcription of several NTFs, 
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including FGF and IGF-1 [125,126]. CNTF has also shown an ability to mediate DAergic 
innervation and promote neuroplasticity and neurogenesis of DAergic neurons from the 
subventricular zone (SVZ) and dentate gyrus in adult mice [127,128]. 
The fibroblast growth factors (FGFs) are a large family of 22 members with diverse 
functions in development, metabolism, and neural activities [129]. The FGFs bind to the fibroblast 
growth factor receptor (FGFR), a receptor tyrosine kinase, which autophosphorylates and activates 
several downstream pathways including MAPK, PI3K/Akt, and PLCℽ [130,131]. Several FGFs 
have been implicated in PD. For example, FGF20 binds to a receptor (FGFR-1C) that is highly 
expressed in the SN and, through activation of the MAPK pathway, is essential for the survival of 
DAergic neurons [132]. Similarly, FGF2 has been shown to have neuroprotective effects on 
DAergic neurons both in cultured neurons and in a rat 6-OHDA PD model [133]. Lastly, basic 
fibroblast growth factor (bFGF) has shown to be neuroprotective in 6-OHDA lesioned rats and in 
culture by activation of the PI3K/Akt pathway to promote survival [131]. 
 
Neurotrophic Factor Effects on Transcription Factors 
NTF signaling stimulates many signaling cascades, in this review, we concentrate on the 
aforementioned MAPK, PI3K/Akt, and PLCℽ pathways (Fig 4). These pathways activate 
numerous transcription factors, such as cyclic adenosine monophosphate (cAMP) response 
element-binding protein (CREB) and nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB), triggering expression of genes involved in cell survival and maintenance of cellular 
function, while inhibiting pathways leading to cell death [121,134,135,136]. The exact 
mechanisms and specific examples will be discussed in appropriate sections. Paramount to the 
survival of DAergic neurons, CREB is directly involved in regulating TH expression in PD 
[137,138], where tyrosine kinase receptor activation is responsible for CREB transcription, thus, 
playing a crucial role in exercise-dependent neuroplasticity [70]. Furthermore, PA induces 
neuroplasticity, not 
only under normal 
physiologic conditions, 
but also in times of 
CNS insult. This PA-
induced neuroplasticity 
occurs by increasing 
TH enzymatic activity, 
acting on the survival 
and synthesis of 






NEUROPLASTICITY AND SYNAPTIC TRANSMISSION 
Neuroplasticity refers to the ability of the nervous system to respond and adapt to 
environmental challenges and encompasses structural and functional mechanisms that may lead to 
neuronal remodeling, formation of novel synapses, and neurogenesis [140]. Aside from their 
known function in supporting neuronal survival, it is now well established that NTFs mediate 
neuroplasticity in adulthood where they modulate axonal and dendritic growth and remodeling, 
membrane receptor trafficking, neurotransmitter release, and synapse formation and function 
[141]. 
Neurogenesis occurs when neural progenitor cells (NPCs) undergo asymmetric divisions 
and can produce neurons or glial cells. Numerous signaling pathways are involved in determining 
the fate of NPCs including growth factors, cytokines, and neurotransmitters [142]. Glutamate is a 
neurotransmitter that indirectly stimulates neurogenesis via the production of NTFs, namely 
BDNF and IGF-1, which promote neurogenesis [143,144]. Furthermore, BDNF’s neurogenic 
action is potentiated through a positive feedback loop with nitric oxide (NO) in differentiating 
neurons, to inhibit NPC proliferation and promote neuronal differentiation [145]. In a study by 
Tajiri et al [50]. 6-OHDA lesioned rats were subject to treadmill exercise to investigate motor 
function, cell survival and changes, and NTF levels. Results showed motor function improvement, 
preservation of TH-positive fibers and DAergic neurons in the striatum and SN, and increased 
levels of BDNF and GDNF. Importantly, using neuronal staining, significantly higher numbers of 
cells were located at distances of 100-200µm and 200-400µm away from the SVZ. 
DA deficiency in PD leads to structural changes in synapses and functional changes in the 
form of neurotransmitter imbalance. On the structural and functional levels, the most well-known 
interactions in the basal ganglia (called the striatum in rodents) are on dendritic spines of medium 
spiny neurons (MSNs), which serves as the interface for signaling of the DAergic and 
glutamatergic systems [146,147]. Dendritic spine loss of MSNs has been observed in animal 
models of PD with DA depletion [148]. The neurotransmitter imbalance brought on by DA loss 
can lead to excessive activation of glutamate receptors, called excitotoxicity. As the name implies, 
excitotoxicity can kill neurons, especially those under conditions of reduced energy supply or 
increased oxidative stress during neurodegeneration [149]. These changes correspond to increased 
glutamatergic signaling and hyperexcitability of neurons [147]. The prolonged and elevated levels 
of glutamate within the synapse results in longer depolarization and ion homeostasis disturbances, 
ultimately leading to cell death. 
One possible neuroprotective effect of PA may be restoration of structural basal ganglia 
circuitry through increases in spine density (Fig 5). In MPTP-lesioned mice, Toy et al [55]. found 
that a 90% loss in DA led to a ~20% dendritic spine loss in MSNs. However, with 6 weeks of 
treadmill exercise after the lesion, results showed reversal of dendritic spine less, enhanced 
dendritic arborization, and increased synapse formation shown by expression of both presynaptic 
(synaptophysin) and postsynaptic (PSD-95) proteins. These same results were demonstrated in a 
second study by Shin et al [47]., however, they also discovered an amelioration in DAergic neuron 
loss. Both experiments also presented that exercise normalized MPTP-induced motor deficits. 
HPT 16 
 
Evidence shows that NTFs are responsible for the outgrowth of axons and dendrites [70]. 
This can be illustrated by two experiments [150,151] that show a knockout of BDNF or its receptor, 
TrkB, led to dendrite and spine reduction in several brain regions, with MSNs being especially 
sensitive. Furthermore, in mesencephalic DAergic neurons, NTF increases the length and branch 
number of neurites on DAergic cells [152]. The growth-promoting effect on neurites is mediated 
by both transcription-independent and -dependent mechanisms, meaning NTFs may influence 
local cytoskeletal dynamics via Ca2+ and kinase-mediated mechanisms, or induce expression of 
genes that encode cytoskeletal proteins and cell adhesion molecules [142]. For example, the 
MAPK pathway, which is activated by several NTFs, is involved in synapse formation and 




NTFs have also been shown to regulate synaptic transmission and neurotransmitter 
concentration by enhancing ion channel function [155], increasing neurotransmitter levels [156], 
and increasing Ca2+-binding proteins involved in neurotransmission [157]. For example, bFGF, 
NGF, and BDNF have shown to protect against glutamate toxicity by inducing antioxidant defense 
systems and stabilizing Ca2+ concentrations [158]. Additionally, through their action at the 
presynaptic terminal, NTFs influence synaptic vesicle docking, fusion, and recycling [159]. This 
is highlighted by the action of BDNF on the presynaptic proteins like Synapsin I. BDNF acts 
through PLCℽ in this pathway to modulate Synapsin functions, including increased 
neurotransmitter release, transporter regulation, and regulation of vesicular release [70]. 
Another possible neuroprotective effect of PA may be functional restoration of 
neurotransmission (Fig 6). With 4 weeks of exercise in PD rat models, Chen et al [154]. reported 
a normalization of the increased glutamate levels and decreased excitotoxicity to MSNs. 
Importantly, yet somewhat redundantly, this review has provided an abundance of evidence to 
show that exercise increases DA levels in the brain. This is highlighted in work by Tillerson et al 
[53]., where they show that up to 4 weeks of treadmill exercise in a rat 6-OHDA model of PD 
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increased striatal levels of DA, DA metabolites (DOPAC, HVA), DA transporters (DAT, VMAT), 
and survival of DAergic cells. These changes are likely due to the action of NTFs, shown by their 
ability to increase supply of transcription factors that induce genes responsible for DA metabolism, 
including TH and AADC [89]. Taken together, PA-dependent neuroprotection may work through 
a mechanism that mitigates corticostriatal hyperexcitability, modulates DA signaling, and/or 




ANGIOGENESIS AND VASODILATION 
PA induces changes including improved synaptic plasticity and neuroprotection that may 
be conferred by an increase in the number (angiogenesis) and diameter (vasodilation) of cerebral 
blood vessels (Fig 7a) following exercise in several brain regions including the motor cortex, 
cerebellum, and midbrain [162,163]. There is also evidence of a relationship between angiogenic 
factors and neurogenesis as neurogenic regions, like the SVZ and dentate gyrus, where new cells 
are clustered close to blood vessels and proliferate in response to vascular growth factors 
[164,165,166]. Vascular changes resulting from exercise are likely mediated by VEGF and IGF-1 
(Fig 7b,c), as gene expression of these growth factors were increased with exercise and a blockade 
of peripheral VEGF and IGF-1 inhibited the neurogenic increase observed with exercise in rodent 
models [167,168]. 
In one study, cerebral angiogenesis was induced in aging rats that were exercised on a 
treadmill 30 min/day for 3 weeks. An increase in the density of microvessels was found within the 
cerebral vasculature, as well as an increase in angiogenic factors such as angiopoietin 1, 
HPT 18 
 
angiopoietin 2, and VEGF [169]. Another study demonstrated a similar result in an MPTP-induced 
PD mouse model that were treadmill-exercised 40 min/day for 4 weeks. Results showed increases 
in blood vessel density and striatal angiogenesis markers VEGF and CD34 in exercised PD mice 




Increased angiogenesis and vasodilation improve microcirculation around DA neurons and 
fibers in the brain. This likely promotes survival of DA neurons via several indirect mechanisms 
including: (i) increased availability of NTFs and biomolecules to neuronal cells through increased 
circulation and vascular permeability, allowing for survival and enhanced functionality; (ii) 
removal of waste materials and maintenance of cellular homeostasis; (iii) proliferation and targeted 
passage of glial cells, causing an upregulation in antioxidant and NTF secretion [100,147,170]. 
 
OXIDATIVE STRESS AND MITOCHONDRIAL FUNCTION 
Mitochondria are essential for many diverse processes in the cell, including energy 
metabolism, calcium buffering, and apoptosis. These organelles are often referred to as the 
“powerhouse of the cell” because they generate the cellular supply of energy in the form of ATP. 
They are also the main source of reactive oxygen species (ROS) which, at normal physiological 
levels, play important roles in several cellular signaling pathways. Therefore, they are most 
susceptible to damage by oxidative stress on DNA, lipids, and proteins [171]. Accumulations of 
ROS can lead to mutations in mitochondrial DNA and misfolding/aggregation of proteins, which 
can disrupt normal cellular functions [172]. Protein misfolding and aggregation will be discussed 
in the next section on protein misfolding and mitochondrial function. Neuronal cells are especially 
vulnerable to the functional deterioration of mitochondria, mostly due to their high energy 
demands, which has been highly implicated in PD [173,174]. 
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It has been discovered that there are higher amounts of common deletions in mitochondrial 
DNA of the surviving DAergic neurons in the SN and are believed to be the result of oxidative 
damage [175]. The “mitochondrial dysfunction” hypothesis of PD was reinforced upon discovery 
of mutations in several genes (e.g., PINK1, DJ-1, PARK2,7, Parkin) that encode mitochondrial 
proteins, giving rise to an inherited form of PD [176,177]. Genetic models of PD also provide 
evidence for increased oxidative stress. Loss of PINK1 function was associated with increased 
ROS production in midbrain neurons by high Ca2+ ion concentrations in the cytoplasm, leading 
to superoxide overproduction. ROS production subsequently inhibits the membrane glucose 
transporter causing dysregulation of mitochondrial metabolism [178,179]. 
Elevated cell death in the SN due to oxidative stress may occur due to (i) greater ROS 
production because of increased DA turnover, (ii) an attenuated ability of the brain to rid of ROS 
because of antioxidant deficiency (e.g., glutathione (GSH), superoxide dismutase (SOD), catalase 
(CAT)), or (iii) production of ROS brought about by elevated levels of neurochemical insult, such 
as heavy metals [180,181]. It has been suggested that depletion of GSH in astrocytes due to 
increased oxidant production could decrease glia mediated GSH release, and thus, deplete GSH in 
neurons [182] and increase exposure to ROS. Rotenone- and MPTP-induced PD animal models 
have both demonstrated the oxidative stress model. MPP+ and rotenone inhibit ATP synthesis by 
blocking electron transport along the electron transport chain (ETC), specifically, through 
inhibition of complex I, resulting in the overproduction of ROS. This provides evidence to the 
view that MPP+ is a mitochondrial toxin, and its neurotoxic effects can be effectively prevented 
by antioxidants [176,183,184]. 
The ability for NTFs to prevent cell death, through reduction in oxidative damage, has been 
shown in vitro. DAergic SHSY-5Y cells treated with 6-OHDA or MPP+ displayed cell death due 
to oxidative damage, shown by a 5-fold increase in oxidized GSH. Treatment of the cells with 
BDNF, however, prevented the rise in oxidized GSH and increased levels of the protective enzyme 
GSH reductase, preventing cell death [185]. A similar result of NTF-neuroprotection to oxidative 
damage was seen in mesencephalic cell cultures treated with 6-OHDA. bFGF treatment of cells 
increased levels of GSH, which was also noted in cells treated with 6-OHDA alone. This 
upregulation of antioxidant defense systems from bFGF was further validated by treatment with a 
GSH inhibitor, which diminished bFGF protection [186], and that neuronal cells upregulate 
transcription of GSH in times of oxidative stress from 6-OHDA or H2O2 [170]. 
Reduction in oxidative stress has also been noted in several in vivo studies that examine 
exercise-induced production of antioxidants. A study by Tuon et al [54]. reports that 8 weeks of 
treadmill training in rat 6-OHDA PD models increased striatal levels of antioxidant enzymes SOD, 
CAT, and GSH peroxidase, and reduced oxidative damage to lipids and proteins. These results 
coincided with increased levels of BDNF, TH, and a reduction in the apomorphine-induced 
rotational test. Several other studies report exercise-induced decreases in oxidative stress caused 
by NTF-mediated upregulation of antioxidant systems [42,158]. 
In a more recent study [187], 4 weeks of treadmill exercise in a rat MPP+ model of PD led 
to expression of nuclear factor erythroid 2-related factor 2 (Nrf2), a regulator of expression of 
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several antioxidant enzymes in the nigrostriatal system. Exercise-induced expression of Nrf2 
prevented the MPP+-induced downregulation of antioxidant enzymes and protected nigrostriatal 
DAergic neurons from degeneration. It has previously been reported that Nrf2 resides in the 
cytoplasm and, only after suitable oxidant stimulation, translocates to the nucleus [250]. It has 
since been discovered that BDNF controls one avenue of Nrf2 translocation to the nucleus to 
upregulate production of antioxidant enzymes [189]. Other NTFs, MANF and CDNF, display an 
antioxidant-like protective role against oxidative stress from the ER [115], which will be discussed 
in the proceeding section on protein misfolding. 
Although this review will not provide an in-depth look at mitochondrial mechanisms of 
apoptosis, it is important to understand that these organelles participate in cell death by releasing 
various cytotoxic proteins in response to numerous signals or lack thereof. These proteins, such as 
cytochrome c, are released from mitochondria through a membrane pore and activate caspases in 
the cytoplasm and nucleus, which dismantle cellular contents and signal for efficient phagocytosis 
of cellular corpses by microglia. Because of the lethality of this process, tight regulation is required 
to prevent accidental activation. Regulation of mitochondrial permeability is carried out by the 
pore-forming Bcl-2 family proteins, composed of two classes: antiapoptotic proteins, notably Bcl-
2, and proapoptotic proteins, notably Bax. Further regulation occurs in the cytoplasm where 
inhibitors of apoptosis (IAP) proteins exert an inhibitory effect on caspase activity. To override 
inhibition of IAP action, proteins such as Smac (also called DIABLO) and Omi (also called 
HtrA2), cause apoptosis by binding to or degrading IAPs, respectively [190]. For a more detailed 
review of apoptosis, please reference the appropriate literature. 
As previously discussed in the section molecular mechanisms of neurotrophic factor action, 
many NTFs trigger intracellular signaling pathways MAPK, PI3K/Akt, and PLCℽ. Activation of 
these pathways results in upregulation of antiapoptotic proteins, including Bcl-2 and Bcl-X, and 
downregulation in proapoptotic proteins such as Bax, BAD, FOX, JNK, p38, and p53. Adjustments 
in apoptotic proteins by NTFs diminishes release of cytochrome c from the mitochondrial 
membrane and extinguishes caspase activation [121,134,135,136,191]. 
Exercise-induced protection of DAergic neurons has also been shown to occur via 
improvements in mitochondrial function. In a mouse model of PD, mice that exercised on a 
treadmill for 18 weeks beginning 1 week before 5-week treatment with MPTP exhibited improved 
mitochondrial function, displayed by increased oxygen consumption, oxidative respiration, and 
ATP production. Furthermore, through upregulation of BDNF and GDNF, results showed that 
improved mitochondrial function leading to DAergic neuron survival was NTF-selective and 
region specific, as NTFs were elevated predominantly in the SN [42]. 
A similar result was seen in Koo et al [40], where MPTP administration followed by 
treadmill training for 8 weeks reduced DAergic neuron loss by altering mitochondrial protein 
levels in three ways: (i) apoptotic pathways were shunted due to an increase in Bcl-2 and decreases 
in both Bax and caspases; (ii) expression of mitochondrial membrane transport proteins, 
responsible for import of structural and functional proteins, was elevated; and (iii) there was an 





Although the detailed mechanisms are exceedingly complex and not fully understood, 
NTFs likely participate in a positive feedback loop with increases in metabolism to reduce 
oxidative stress and improve mitochondrial function, rather than initiate the processes on their 
own. This can be exemplified by preceding discussion on exercise-induced PGC-1ɑ production. It 
was shown that exercise increases levels of PGC-1ɑ, leading to increased metabolism and 
production of metabolic intermediates, which then caused an upregulation of NTFs [61,62]. PGC-
1ɑ expression not only causes mitochondrial biogenesis, it also increases the functionality of 
mitochondria by increasing mitochondrial protein production, enzyme activity, and mitochondrial 
DNA [192]. Marked increases in metabolism also incur increased oxygen consumption, which 
would decrease production of ROS, and thus, oxidative damage on mitochondrial DNA leading to 
dysfunction and protein aggregation. 
 
PROTEIN MISFOLDING AND MITOCHONDRIAL FUNCTION 
The detection of Lewy bodies (LBs) in the SN and other brainstem nuclei has long been 
considered the pathogenic hallmark of PD. During the development of PD, cellular defense 
mechanisms to deal with misfolded protein aggregates, including the unfolded protein response 
(UPR), molecular chaperones, the ubiquitin-protease system (UPS), and autophagy are 
compromised [193]. LBs are protein aggregates of ɑ-syn and other biomolecules from 
microtubules, mitochondria, lysosomal and autophagy pathways [194]. 
Studies show that mutant protein, ɑ-synuclein (ɑ-syn), can induce the UPR in the ER, 
which induces adaptive cell death in response to pathologic conditions such as nutrient deprivation, 
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disruption of Ca2+ homeostasis, viral infection, and secretory protein mutations [195]. In addition, 
ɑ-syn in LBs also block ER vesicles from docking with the Golgi apparatus leading to vesicular 
accumulation [196]. MANF and CDNF are important in the reduction of ER stress and prevention 
of apoptosis through UPR [115]. These NTFs were shown to be upregulated with exercise and act 
as a neuroprotectant in a 6-OHDA rat PD model. Results of the study showed a decrease in the 
apomorphine rotation test, increased DA concentration, and ameliorated levels of DAergic neurons 
[43,197]. Furthermore, the lack of MANF in a mouse model leads to activation of UPR [198]. The 
exact mechanism of neuroprotection was, however, elucidated in cell studies. 
In two studies using DAergic SHSY-5Y cells, 6-OHDA or ɑ-syn overexpression were used 
to model ER stress-induced apoptosis. These studies found that MANF treatment significantly 
upregulated the molecular chaperones HSP70 [199] and GRP78 (also called BiP) [200]. In 
addition, they saw a marked decrease in caspase activation. This suggested that upregulation of 
molecular chaperones, involved in the rescue of misfolded proteins [201], alleviates ER stress and 
protects DAergic neurons from apoptosis. Both studies validated their predicted mechanisms by 
overexpressing the molecular chaperone of interest to inhibit 6-OHDA-induced apoptosis, and by 
using knockouts of the molecular chaperone to block MANF-induced cell survival. 
These NTFs can also be secreted to exert their neuroprotective effects in times of excessive 
ER stress. For example, MANF can bind to and block the proapoptotic molecule Bax, preventing 
cell death [118]. Furthermore, they have also demonstrated binding and internalization of oxidized 
lipids at the cell surface, reducing ER stress and UPR pathways [114]. 
The UPS is the major non-lysosomal pathway for protein breakdown (proteolysis). The 
destination of the UPS, the proteasome, is a complex of enzymes responsible for intracellular 
proteolysis of proteins marked for degradation by ubiquitin tags. Alterations in proteasome 
function of protein clearance have been implicated in PD, where formation of abnormal protein 
aggregates (e.g., LBs), resulting from proteasome inhibition, activate intracellular UPRs, causing 
oxidative stress and apoptosis [202]. It still remains unknown if NTFs act directly on the UPS to 
promote protein aggregate clearance and cell survival, or if NTFs simply ameliorate the survival 
of neurons despite dysfunction and apoptotic signals; however, several theories have been 
proposed. Two of which being that (i) NTFs stimulate UPS-mediated proteolysis through 
enhancing the expression of ubiquitin enzymes and proteasome subunits, and (ii) NTFs preserve 
proteasome function and attenuate toxicity of proteasome inhibition [203]. 
The first hypothesis was shown in Jho et al [204]. where CNTF upregulated the 20S 
proteasome, a component of the proteolytic core. However, this result was obtained from hepatic 
cells and it is unknown if CNTF would have the same effect on neurons. The second hypothesis 
was shown using BDNF and GDNF. Santos et al [205]. suggested that BDNF downregulated 
proteasome activity in cultured hippocampal neurons and Du et al [206]. found GDNF protects 
nigral DAergic neurons in a PD mouse model from UPS impairment-induced degeneration. 
Lastly, autophagy is an autonomous cell survival mechanism that maintains homeostasis 
by catabolically degrading misfolded proteins and clearing excess or damaged organelles by 
isolating them in double-membraned structures, eventually fused with lysosomes [207]. BDNF is 
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known to signal in several pathways. One of which, the PI3K/Akt pathway, is upstream of the 
mammalian target of rapamycin (mTOR), which is fundamental in the induction of autophagy 
[208]. While mTOR is most often discussed for its role in autophagy, it is also involved in several 
cellular processes, including protein synthesis, cell growth, proliferation, survival, and synaptic 
plasticity [209]. 
In one study, researchers investigated the neuroprotective effect of BDNF through the 
PI3K/Akt/mTOR pathway in cortical rat neurons, subject to oxygen deprivation (hypoxia). Their 
results demonstrated that BDNF acted as a neuroprotectant by promoting cell viability via the 
upregulation of autophagy, which is essential to maintaining cellular homeostasis when responding 
to stress [208]. On the other side of the mTOR pathway, CNTF was shown to activate a signaling 




Similar to the discussion in the previous section, decreases in protein 
misfolding/aggregation cannot be entirely attributed to NTF action, but rather, NTF action in 
combination with improved mitochondrial function. Through increased oxygen consumption and 
decreased oxidative damage to mitochondrial DNA and proteins, there would be a reduced amount 
of misfolded proteins and an increase in antioxidant enzymes which would reduce oxidative 
damage [211]. The previous section discussed how oxidative damage to mitochondrial DNA leads 
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to mutations in inherited forms of PD. Here, the aberrant functionality of these gene products can 
be demonstrated using two of the most common inherited gene mutations, Parkin and PINK1. 
Narendra et al [212]. showed that these two gene products are involved in a mitochondrial quality 
control pathway that identify dysfunctional mitochondria and mark them for destruction by 
autophagy. Similarly, Moscovitz et al [213]. found that the DJ-1 gene plays an important 
regulatory role in the function of the 20S proteasome ‒ part of the UPS. 
 
NEUROINFLAMMATION 
PA’s neuroprotective effect has been linked to the modification and prevention of the 
neuroinflammatory process [214], which has been shown to play a role in the pathogenesis of 
animal PD models via the increase of pro-inflammatory cytokines, chemokines, and ROS that 
trigger the initiation of extrinsic neuronal apoptosis [215] and activate both microglia and 
astrocytes in response to ɑ-syn aggregates and necrotic neurons [216,217]. Glial cells may be 
activated in two different ways ‒ a pro-inflammatory (classical M1 activation) or an anti-
inflammatory (alternative M2 activation) response. In the M2-type response, microglia increase 
their expression of anti-inflammatory cytokines and NTFs including IL-6, IL-10, TGFβ, IGF-1, 
NGF, and BDNF [218]. Astrocytes also secrete anti-inflammatory compounds and NTFs such as 
GDNF, BDNF, and MANF, serving to restore functionality and promote survival to injured 




In a study by Real et al [45]., 6-OHDA-lesioned rats were subject to treadmill exercise for 
4 weeks or a sedentary lifestyle. Lesioned PDS animals displayed an increase in 
neuroinflammatory markers in the SN and striatum, as well as an increase in the astrocyte, 
HPT 25 
 
microglial, and oxidative species activation. On the other hand, the lesioned PDE animals did not 
show neuroinflammatory responses and performed better on the apomorphine-induced rotation 
test. Jang et al [39]. investigated the effects of exercise endurance in an MPTP PD mouse model, 
specifically monitoring the interplay between ɑ-syn levels accompanied by neuroinflammation 
and the anti-inflammatory effects of exercise. Results showed increased motor function and 
reduced cell death by reestablishment of TH levels when compared to PDS controls. PDE mice 
showed a reduction in the ɑ-syn protein and pro-inflammatory cytokines, preventing activation of 
apoptotic signaling cascades incurred by MPTP striatal administration. 
One of the long-standing theories proposes that PA regulates immune function through 
enhanced secretion of muscle-derived cytokines and peptide hormones (myokines), including 
several known NTFs. Importantly, there have been shown to cross the BBB and act in an anti-
inflammatory mechanism on the CNS by upregulating the expression of proteins with strong anti-
inflammatory, anti-oxidative, and anti-apoptotic properties (e.g., metallothionein) [220,221]. 
Additionally, macrophages and T-regulatory cells produce NTFs, in response to secretions from 
skeletal muscles, which act in an anti-inflammatory manner to inhibit the production of pro-
inflammatory cytokines (e.g., IL-1ɑ, IL-1β, and TNF-ɑ) [222]. 
The role of exercise induced NTF neuroprotection against inflammatory insult was perhaps 
best demonstrated in Wu et al [57]. by showing the BDNF signaling pathway protects DAergic 
neurons. Researchers allowed 4 weeks of treadmill exercise prior to injection of LPS to induce PD 
in a mouse model, brought on through microglia activation in the SN. Exercise prior to LPS 
treatment completely prevented the reduction in DAergic neurons, DA in the striatum, BDNF 
levels in the SN, and impaired motor coordination. In this study, results were attributed to the 
restored levels of BDNF signaling, protecting DAergic neurons against inflammation-induced 
insult. 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
Pharmacological and surgical treatment of PD are often ineffective, and the benefits seen 
decrease with disease progression, likely because the disease is multifactorial both in its cause and 
development. PA is non-invasive, -pharmacological, and causes no side effects. Although PA has 
many known benefits through the increased mobilization of NTFs, the mechanisms are not fully 
understood. 
Studies in animal models of PD (Table 2) indicate that PA may prevent the loss of, protect, 
or restore DAergic neurons and improve motor function. PA likely enhances the overall metabolic 
state, which leads to an increased synthesis and release of NTFs. These NTFs then activate several 
signaling cascades to exert their effects on neuronal cell populations. 
Studies in animal models elucidate how NTFs can improve functionality in many aberrant 
cellular mechanisms seen in PD, which this review has laid out in four main parts: (i) the brain is 
better equipped to adapt to abnormal structural and functional changes through neurogenesis, 
neuroplasticity, and refined neurotransmission; (ii) cerebral blood flow is improved through 
angiogenesis and vasodilation; (iii) mitochondrial function, and thus, metabolism are boosted by 
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reducing oxidative stress and preventing protein misfolding/aggregation; and (iv) self-harm is 
eliminated by mitigating neuroinflammation. 
Although, utilizing neurotoxins in animal models do not completely reproduce the etiology 
of PD in humans. While commonly used to study the pathogenesis, progression, and effectiveness 
of disease treatment, when a neurotoxin is administered, PD is induced, rather than being brought 
on systemically. Additionally, motor control in animal models is not as hierarchical and human 
locomotion receives more contribution from the cerebral cortex and subcortical structures. 
The cellular mechanisms in this review on how PA mediates neuroprotection could be 
entirely practical; however, more research is needed to establish these mechanisms and elaborate 
their details. For translational and clinical research in humans, it is important to determine when 
to start and what form, intensity, and duration of PA is needed to produce the maximal behavioral, 
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